IGF2BP3 and hepatocellular carcinoma: In HCC, Lu et al. (2024) demonstrated that the lactylation of IGF2BP3 stabilizes phosphorenolpyruvate carboxykinase (PCK) and nuclear factor erythroid 2-related factor 2 (NRF2), ultimately promoting resistance to levatinib.